New Buy Alert: Here's Your Prescription for Profits with Front Trader's Favorite Biotech

Investors sold off their stock shares in droves last month, but front traders stepped in to buy as the fearful ran for the exits. And their favorite small cap biotech company is our next trade target.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Zach’s Weekly Squawk Box


You May Also Be Interested In:

The Latest From Our Favorite Activist Investor

Major indexes are overreacting to every headline – but as an investor, what you should really care about is what’s happening behind closed doors. And today, Zach takes a look at a pair of companies that have given us cause for concern… and decides whether they still deserve a spot in our portfolio.

Zach Scheidt

Zach Scheidt is the editor of Lifetime Income Report, Income on Demand, Buyout Millionaires Club, Weekly Squawk Box and Family Wealth Circle — investment advisories dedicated to finding Wall Street’s best yields. He brings to the table impeccable investment management experience and a solid record of identifying oversized payout opportunities.

Zach previously edited Income and...

View More By Zach Scheidt